ROIV (Roivant Sciences) Institutional Ownership: 79.66% (As of Jul. 02, 2026)


ROIV Roivant Sciences Ltd ROIV
55 GF Score
Price $35.13
GF Value $10.95
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Institutional Ownership?

Roivant Sciences ROIV +0.29% 55 Institutional Ownership is 79.66% as of Jul. 02, 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $10.95 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Roivant Sciences's institutional ownership is 79.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Roivant Sciences's Insider Ownership is 13.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Roivant Sciences's Float Percentage Of Total Shares Outstanding is 75.84%.

Roivant Sciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Institutional Ownership Chart

Roivant Sciences Historical Data

The historical data trend for Roivant Sciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 39.02 40.07 40.16 41.92 42.52 43.15 43.48 43.40 43.75 44.14
ROIV
55GF Score
Roivant Sciences Ltd ROIV
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 79.66% mean?
Roivant Sciences (ROIV) has a Institutional Ownership of 79.66% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' Institutional Ownership too high?
Roivant Sciences' current Institutional Ownership is 79.66%. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Institutional Ownership compare to RPRX and BNTX?
Roivant Sciences' Institutional Ownership of 79.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Institutional Ownership is 79.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.95, compared to a current price of $35.13 — trading 220.8% above its estimated fair value. The current Institutional Ownership is 79.66%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Institutional Ownership is 79.66% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $35.13 is trading 220.8% above its estimated GF Value™ of $10.95. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Institutional Ownership: 79.66%
  • GF Value™: $10.95 vs. price of $35.13 (220.8% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIV

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.13
Price
$10.95
GF Value